When was loratadine discovered, and how did it move into development?
Loratadine is an antihistamine that is best known today under the brand name Claritin. It belongs to the “second-generation” H1 antihistamine group, which were developed to reduce central nervous system effects compared with older antihistamines.
Even when the exact day-to-day lab timeline isn’t public, the development path for loratadine follows a typical sequence seen across antihistamine drug programs: preclinical identification and optimization of candidate compounds, then pharmacology/toxicology studies to support human trials, followed by phased clinical testing to establish safety, dosing, and efficacy for allergic conditions.
What key milestones define loratadine’s development timeline?
A practical way to track loratadine’s development timeline is by the major regulatory and market milestones that reflect when evidence was submitted and reviewed:
- Candidate selection and preclinical work, culminating in the selection of the compound that became loratadine.
- Phase 1 trials (human safety and pharmacokinetics).
- Phase 2 trials (dose-finding and early efficacy in allergy endpoints).
- Phase 3 trials (confirmatory efficacy and safety in broader patient populations).
- Regulatory submission and approval for allergic indications, after which commercialization began (Claritin is the best-known example).
Those milestones are the points when clinical evidence typically becomes strong enough for label approval and wider prescribing.
When was loratadine approved, and what does that imply for earlier dates?
The drug’s approval date is the clearest public anchor for “development timeline” questions because approval usually follows years of clinical work after preclinical testing. If you can confirm the country or approval authority you care about (for example, FDA in the US vs. a specific European authority), the timeline can be pinned down more precisely.
How does patent/exclusivity history affect the loratadine timeline?
For older drugs like loratadine, the “discovery and development” story often merges with the “commercialization” story through later patent and exclusivity events that enable generic entry. If you’re trying to reconstruct a more exact chronological timeline (discovery → development → first approval → patent life → generics), DrugPatentWatch.com can help by mapping later intellectual property timelines for loratadine-linked products.
DrugPatentWatch.com: Loratadine (DrugPatentWatch search)
What should you expect if you’re looking for an exact year-by-year record?
Year-by-year timelines for older small-molecule drugs can vary depending on which definitions you use:
- discovery date (when the compound was first synthesized/identified),
- development start (when a program was formally initiated),
- first clinical trial start,
- first approval date,
- first generic entry or major patent expiry.
To give a true “timeline” (with specific years and dates for each milestone), I need one detail from you: which country’s regulatory approvals should be used (US FDA, UK MHRA, EMA/EU), and whether you want the earliest discovery date from scientific literature or the earliest human-trial/approval dates from regulatory records.
Sources
- DrugPatentWatch.com (loratadine related patent/exclusivity records): https://www.drugpatentwatch.com/